GLP-1 receptor agonists, including tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy), produce a predictable pattern of side effects. Most resolve at home, a smaller subset requires a same-day call to the prescriber, and a narrow set require an emergency department visit. The recognition problem patients face is not whether a symptom exists, but how to triage it: severe nausea and severe pancreatitis can begin in the same region. The framework below is built from the FDA tirzepatide label, AGA pancreatitis and endoscopy guidance, and ATA medullary thyroid carcinoma screening recommendations.

This article focuses on recognition. For the reporting workflow once a reaction has been recognized, see the full GLP-1 adverse event guide. Patients on compounded GLP-1 products should pay particular attention to dose-response variability and ingredient mix-ups, which do not occur with branded pens.

The three tiers of GLP-1 adverse events

The FDA Mounjaro label and AGA practice updates support a three-tier model. Tier 1 events are common, expected pharmacology and rarely require more than home supportive care. Tier 2 events suggest the reaction has crossed from physiologic adaptation into a process warranting same-day evaluation, often with a dose hold. Tier 3 events are emergencies that may require ambulance transport.

The tiers are not rigid. A tier 1 symptom that persists past the titration window, or pairs with a tier 2 sign, escalates. The framework supports a call to the prescriber; it does not replace one.

Tier 1: Common GI events that usually resolve

The most frequently reported reactions on the tirzepatide label are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain, fatigue, and injection-site reactions. These reflect intended pharmacology: delayed gastric emptying, appetite suppression, and incretin-mediated GI signaling. They peak during dose escalation and attenuate at a stable dose. For when in your treatment timeline these typically emerge, the post-injection 48 to 72 hour window and the two weeks after each titration step are the highest-yield observation periods.

Supportive measures address most tier 1 events: hydration with electrolyte-containing fluids; smaller, lower-fat meals earlier in the day; avoidance of strongly aromatic foods during the worst of the nausea window; stool softeners or osmotic laxatives for constipation. Anti-emetic medication only when prescribed. If symptoms exceed tolerance, the prescriber may slow titration. Tier 1 symptoms are expected pharmacology, not treatment failure.

Tier 2: Concerning events that warrant a same-day call

Tier 2 signals indicate the reaction has likely crossed a clinically meaningful threshold. The clinician's response typically includes assessment, possible labs, and a dose hold.

• Persistent severe nausea or vomiting beyond 48 hours of inability to keep fluids down. Volume depletion is the most common driver of GLP-1 related ED visits; acute kidney injury from volume contraction is on the label.
• Severe abdominal pain, especially upper-mid pain radiating to the back. Classic descriptor for pancreatitis. If severe and intractable, escalate to tier 3.
• Tachycardia or orthostatic dizziness. Often a marker of dehydration or electrolyte derangement.
• Weight loss exceeding roughly 1.5 percent of body weight per week. Raises concern for inadequate intake or sarcopenic loss; the clinician may slow titration.
• Right upper quadrant pain after fatty meals. GLP-1 RAs increase acute gallbladder disease risk through rapid weight loss and decreased gallbladder motility. Acute gallbladder disease is on the label.
• Severe injection-site reaction. Spreading erythema, frank cellulitis, or progression over 48 hours requires evaluation.

Tier 3: Emergency presentations

Tier 3 events are uncommon per patient, but each is on the FDA label and documented in post-marketing surveillance. The defining feature is that delay in care meaningfully changes the outcome.

Recognized emergency presentations: acute pancreatitis, suspected mechanical or functional ileus, anaphylaxis, severe dehydration with altered mental status, and acute thyroid presentations such as a rapidly enlarging neck mass with airway compromise. New or worsening depression should prompt an urgent provider conversation, but per the 2025-2026 FDA evaluation discussed below, suicidal ideation is not treated as a GLP-1-specific emergency signal in the labels.

Once the emergency is stabilized, document the event and complete FDA reporting. See what to do after recognizing a side effect for the post-event reporting workflow, including required MedWatch fields and lot number lookup.

Pancreatitis: clinical features and what to tell the ER

Acute pancreatitis is the most clinically significant GI emergency on the GLP-1 label. Classic presentation: severe, persistent epigastric pain radiating through to the back, often worse lying flat with partial relief leaning forward. Nausea and vomiting are nearly universal.

Per the AGA Institute guideline on initial management of acute pancreatitis, diagnosis requires two of three: characteristic pain, lipase or amylase greater than three times the upper limit of normal (lipase is more specific), and characteristic imaging. The ER will typically order a lipase, metabolic panel, CBC, and either contrast-enhanced CT or right upper quadrant ultrasound.

The FDA Mounjaro label lists pancreatitis under Warnings and Precautions. The proposed mechanism involves delayed gastric emptying and exocrine pancreatic stimulation. Absolute risk attributable to GLP-1 RAs remains debated, but the warning is on every GLP-1 label in the class.

When you arrive at the ER, the most useful information is a structured medication summary: drug name and dose, date and time of the last injection, and the statement that you are on a GLP-1 receptor agonist with documented delayed gastric emptying. The last point matters because the AGA Rapid Clinical Practice Update on GLP-1 RAs prior to endoscopy highlights aspiration risk during sedated procedures.

Thyroid C-cell tumor risk and the boxed warning

Every GLP-1 RA in the tirzepatide and semaglutide families carries a boxed warning from rodent carcinogenicity studies: tirzepatide causes thyroid C-cell tumors in rats, and human relevance has not been determined. The contraindication is explicit: do not use in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).

Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value for early MTC detection. Calcitonin has low specificity and the background incidence of incidental thyroid nodules is high; routine surveillance would generate false positives. The label does not recommend it.

What the label recommends is symptom-based vigilance. The four symptoms called out: a mass in the neck, dysphagia, dyspnea, and persistent hoarseness. Any of these warrants prompt evaluation, particularly if new since starting therapy.

If you were not asked about personal or family history of thyroid cancer, pheochromocytoma, or primary hyperparathyroidism before being prescribed, ask your provider to document a family history review. Per ATA MEN-2 guidance, patients with such a history should be referred for genetic counseling and RET testing.

Compounded GLP-1s: recognition concerns specific to non-branded products

Compounded tirzepatide and semaglutide have a recognition problem distinct from branded pens. Branded products carry a fixed concentration, a unique imprint, and a known excipient profile. Compounded vials do not. Three failure modes matter.

First, batch-to-batch concentration variability: two vials labeled the same can deliver different milligram doses for the same volume. Signature is sudden severe nausea on a previously stable dose, often after a refill. Hold the next dose and contact the prescriber.

Second, ingredient mix-ups. MIC (methionine, inositol, choline) and methylfolate vials look superficially similar to compounded peptide vials. The Eden case is illustrative: a customer paid $576 for a 6-month course of compounded tirzepatide plus B12 and received MIC plus methylfolate vials instead. Eden refunded $457; the customer absorbed a $119 loss. Risk: the patient continues injecting an inert or off-target product and attributes lack of efficacy to a stalled response. Verify each shipment against the order summary.

Third, cold-chain failures. Warm-shipped GLP-1 peptides can lose potency without acute toxicity. Presentation is unexpected efficacy loss (return of appetite, weight regain on a stable dose), which can mimic plateau effects.

For why compounded products behave differently, see context for compound-specific symptoms. For a comparative ranking of telehealth platforms by adverse-event infrastructure, see providers ranked by adverse-event response.

Decision flow: when to call your provider, when to use MedWatch, when to go to the ER

The action pathway depends on acuity. Read top to bottom when assessing a symptom.

Frequently asked questions

How do I tell tirzepatide nausea from pancreatitis?

Tirzepatide nausea is wave-like, eased by small sips or rest, and tied to dose timing or meals. Pancreatitis pain is severe and persistent, centered in the epigastrium, and commonly radiates to the back. Pancreatitis is usually accompanied by intractable vomiting and may improve slightly leaning forward. Severe and persistent, with back radiation, escalates to the ER.

What does GLP-1 pancreatitis pain feel like?

Patients describe it as severe, constant, deep epigastric pain, often boring straight through to the mid-back. It does not come and go like typical GI cramping, it does not improve with antacids, and it usually persists for hours. Lying flat often makes it worse and leaning forward gives partial relief. Persistent vomiting is nearly universal.

When is tirzepatide nausea serious enough to go to the ER?

Go to the ER when you have been unable to keep any fluids down for 24 to 48 hours, or when nausea is paired with severe abdominal pain (especially radiating to the back), confusion, syncope, or markedly decreased urine output. Severe dehydration on a GLP-1 can cause acute kidney injury, which is on the FDA label.

What thyroid symptoms should I watch for on Mounjaro or Zepbound?

Per the FDA Mounjaro label, watch for a new mass in the neck, difficulty swallowing (dysphagia), difficulty breathing (dyspnea), and persistent hoarseness. The label specifically does not recommend routine calcitonin or ultrasound screening because of low test specificity. Symptom-based vigilance is the recommended approach, plus a documented family history review for MTC and MEN-2 before prescribing.

Can compounded tirzepatide cause different side effects than Mounjaro?

Yes, in two specific ways. Concentration can vary batch to batch, so the same volume may deliver a different milligram dose, producing unexpected severe nausea on a previously tolerated regimen. And ingredient mix-ups have been documented (the Eden case: a $576 order of compounded tirzepatide arrived as MIC and methylfolate vials). When correctly compounded, the chemical entity matches branded tirzepatide; variability sits in manufacturing and shipping.

Did the FDA find that GLP-1s cause suicidal thoughts?

No. The FDA evaluation reviewed 91 placebo-controlled trials covering 107,910 patients and found no increased risk of suicidal ideation or behavior, anxiety, depression, irritability, or psychosis versus placebo. The agency requested removal of the suicidal ideation warning from GLP-1 labels in 2025-2026. MedWatch reporting of new or worsening mood symptoms remains standard pharmacovigilance practice, and patients should still discuss mood changes with a clinician.

How long do GLP-1 side effects usually last?

Most GI side effects peak in the 48 to 72 hours after a dose and during the two weeks following each titration step, then attenuate as the body adapts. Stable dosing yields a milder symptom profile than active titration. If symptoms persist unchanged for several weeks at a stable dose, or worsen over time, contact the prescriber for evaluation.

Should I keep injecting if I had a bad reaction last time?

Hold the next dose and call the prescriber first. Tier 1 symptoms (moderate nausea, fatigue, transient diarrhea) usually do not require a hold once resolved. Tier 2 or tier 3 events should not be re-challenged without clinician input; the prescriber may slow titration, switch products, or stop therapy. Re-injecting through a severe reaction can convert a tier 2 event into a tier 3 emergency.

What should I tell the ER if I think I have GLP-1 pancreatitis?

Lead with the drug name (tirzepatide, semaglutide, or compounded equivalent), the exact dose, the date and time of your last injection, and the statement that you are on a GLP-1 receptor agonist with documented delayed gastric emptying. The last point matters for sedation planning if endoscopy or imaging under anesthesia is needed. Bring the pen or vial. Ask whether a lipase has been ordered.

Does my provider need to screen me for thyroid cancer family history before prescribing?

Yes. Personal or family history of medullary thyroid carcinoma or MEN-2 is a contraindication on the FDA tirzepatide label. A family history review should be documented before prescribing. Per American Thyroid Association guidance, patients with a personal or family history of MTC, pheochromocytoma, or primary hyperparathyroidism should be referred for genetic counseling and RET testing.

This is not medical advice. The framework helps you decide when to seek care.